Press Releases

UK life science backs May's plan to remain part of EMA

BIA welcomes the Prime Minister’s announcement today that the UK will seek to explore with the EU, the terms on which the UK could remain part the European Medicines Agency, abide by the rules of the agency and make an appropriate financial contribution.

Brexit Health Alliance Campaign - The Impact of Brexit: Patient Access to Medical Research

Children could be excluded from lifesaving clinical trials for cancer treatments when the UK leaves the EU, according to the Brexit Health Alliance.

BIA launches new Genomics Advisory Committee at annual Committee Summit

Today the UK Bioindustry Association (BIA) launches its newest Advisory Committee, focused on the issue of genomics.

Harren Jhoti receives BIA Lifetime Achievement Award at Annual Gala Dinner

Harren Jhoti, co-founder of Astex and President and CEO of Astex Pharmaceuticals, was awarded the BioIndustry Association (BIA) Lifetime Achievement Award at the BIA’s annual Gala Dinner last night.


Member News

The Babraham Research Campus appoints Dr Karolina Zapadka to lead Accelerate@Babraham

Experienced life science business development manager to drive development of the new bio-incubator and life science accelerator at the Babraham Research Campus

Fuel3D to establish new headquarters on The Oxford Science Park

Oxford, UK, 19 March 2018 – Fuel3D, which develops innovative 3D scanning solutions across a range of industries, is relocating its UK headquarters to The Oxford Science Park, one of the UK's leading parks for science and technology companies. Expected to move in during June, Fuel3D will be the first occupier of the Park’s new Schrödinger Building, which will accommodate both office and laboratory facilities.

Horizon Discovery and Genewell Biotechnology enter into partnership for distribution of diagnostic reference standards for the Chinese market

Partnership immediately provides Horizon with deeper access to Chinese diagnostic assay manufacturers and potential OEM agreements as part of stated global leadership strategy.

Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation

Astex Pharmaceuticals , a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.


BIA blog

CEO Update: Monday 19 March

It was good to catch up with many BIA members at BioEurope Spring in Amsterdam last week, where the strength on the UK ecosystem was evident. Speaking on two issue panels - one on Brexit and another on AMR - I was struck by the perseverance and endurance of company leadership despite the uncertainties in the policy landscape.

Video of the Week - Dr Elisa Passini on winning the 2017 3Rs Prize

Dr Elisa Passini (Department of Computer Science, University of Oxford) is the 2017 3Rs Prize winner. Here she discusses her prize-winning research into the development of computer models of human cardiac cells for the prediction of drug-induced cardiotoxicity. These have the potential to replace animal models in pre-clinical trials, as well as providing a more accurate model of human cardiac activity.

BIA visits an animal research facility

The BIA team recently visited the animal research facilities at King’s College London. It was the first time many in the team had visited animal research facilities to see how pre-clinical research looks in practice.

Steady as she goes in the Spring Statement

Dr Martin Turner, BIA Policy and Projects Manager, takes a look at today's Spring Statement from Chancellor Phillip Hammond and its implications for the bioscience sector.


Our publications

Please find a selection of featured BIA publications below. To see our full publications library, click here

BIA members' guide to the Patent Box

This guide explains how the Patent Box regime works and what bioscience companies should consider when choosing if and when to elect into it.

Influencing and shaping our sector, BIA update - October 2017 - January 2018

An overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders from October 2017 to January 2018.

Pipeline Progressing: The UK's Global Bioscience Cluster in 2017

A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.

BIA Best practice guide for communicating R&D

Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.